Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protalix Biotherapeutics (NY: PLX )

1.650 +0.030 (+1.86%)
Streaming Delayed Price Updated: 11:45 AM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 292,926
Open 1.670
Bid (Size) 1.650 (20)
Ask (Size) 1.660 (75)
Prev. Close 1.620
Today's Range 1.630 - 1.680
52wk Range 0.7000 - 2.000
Shares Outstanding 50,665,598
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed
 
Via Benzinga

Performance

YTD
+20.45%
+20.45%
1 Month
+20.45%
+20.45%
3 Month
+61.77%
+61.77%
6 Month
+55.68%
+55.68%
1 Year
+87.51%
+87.51%

More News

Read More
Protalix BioTherapeutics Well Placed to Advance in 2023
Via Talk Markets
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via News Direct
Exposures Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via TheNewswire.com
Exposures Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via Benzinga
Earnings Scheduled For May 16, 2022
Via Benzinga
Protalix PRX-102: Likely Approval Could Be A Game Changer
Via Talk Markets
Why Protalix Is Back On The Radar?
Via Talk Markets
Earnings Scheduled For November 14, 2022
Via Benzinga
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via TheNewswire.com
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via News Direct
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via Benzinga
10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up
Via Benzinga
Earnings Scheduled For August 15, 2022
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Why Protalix BioTherapeutics Stock Is Soaring
Via Benzinga
Protalix BioTherapeutics's Return On Capital Employed Insights
Via Benzinga
Recap: Protalix BioTherapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For Protalix BioTherapeutics
Via Benzinga
Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Via Benzinga
Earnings Scheduled For March 31, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.